HMGB1 and neoplasm: Similar to mice in which tumour expression of HMGB1 was silenced or inhibited with recombinant BoxA, mice treated with anti-IL-10 exhibited significantly delayed tumour growth compared to controls, whereas anti-IL-10 did not significantly affect the growth of HMGB1-shRNA-transduced B16 tumours (Fig. 7c).